ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links0 made here, not in the record19 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06908993Tepotinib vs StandardTreatment in Patients WithAdvanced MET Exon 14Mutated Non-Small Cell LungCancer Previously TreatedIntergroupe Francophone de CanPhase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSTepotinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPemetrexedEntry “Pemetrexed (Alimta)”, read by …›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorVinorelbineIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorGemcitabineEntry “Gemcitabine alone”, read by ou…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Tepotinib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Tepotinib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TepotinibClaude Opus 5.5TestedCurrent
Nov 2PemetrexedClaude Opus 5.5ComparatorCurrent
Nov 2VinorelbineClaude Opus 5.5ComparatorCurrent
Nov 2GemcitabineClaude Opus 5.5ComparatorCurrent
Nov 2DocetaxelClaude Opus 5.5ComparatorCurrent
Nov 2PaclitaxelClaude Opus 5.5ComparatorCurrent
Nov 2PembrolizumabClaude Opus 5.5ComparatorCurrent
Nov 2NivolumabClaude Opus 5.5ComparatorCurrent
Nov 2AtezolizumabClaude Opus 5.5ComparatorCurrent
Nov 18TepotinibRule based · role ruleTestedAgrees
Nov 18PemetrexedRule based · role ruleComparatorAgrees
Nov 18VinorelbineRule based · role ruleComparatorAgrees
Nov 18GemcitabineRule based · role ruleComparatorAgrees
Nov 18DocetaxelRule based · role ruleComparatorAgrees
Nov 18PaclitaxelRule based · role ruleComparatorAgrees
Nov 18PembrolizumabRule based · role ruleComparatorAgrees
Nov 18NivolumabRule based · role ruleComparatorAgrees
Nov 18AtezolizumabRule based · role ruleComparatorAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.